Determinants Influencing Glycaemic Control in Elderly Chinese Patients
Diagnosed with Type 2 Diabetes: A Cross-sectional Study
- Lei Cao,
- Shuang-shuang Chen,
- Qing Xu,
- Can Chen,
- Qianzhou Lv,
- Xiaomu Li,
- Xiao-yu Li1*
Abstract
not-yet-known
not-yet-known
not-yet-known
unknown
Abstract Few studies have investigated blood glucose levels and
complication management in elderly patients with type 2 diabetes (T2D)
at community hospitals in China. The objective of this study was to
investigate the factors influencing blood glucose control in elderly
patients with T2D and assess the adherence of doctors in community
hospitals to the latest diabetes guidelines regarding the use of
glucose-lowering medications. This study involved 1150 elderly patients
(age≥65 years) with diabetes to assess blood glucose control,
complications management, and adherence of medication according to the
guidelines of American Diabetes Association. To evaluate blood glucose
control, different glycated haemoglobin targets were assigned according
to patient characteristics and health status (including comorbidities
and cognitive status). Univariate and multivariate logistic regression
analyses were used to investigate the factors affecting glucose control.
Among the 1150 participants, 351 (30.52%) had poor glucose control.
Frailty (odds ratio [OR]:0.393; 95% confidence interval
[CI]:0.195-0.789; P=0.009), male sex (OR:1.472; 95% CI:1.131-1.915,
P=0.004), and insulin treatment (OR:4.364; 95% CI:3.151-6.042;
P<0.001) were significantly associated with poor blood glucose
control in patients treated with glucose-lowering medications. The
proportion of patients without frailty with poor control was higher than
those with frailty (31.28% vs. 17.46%, respectively). In conclusion,
blood glucose control in elderly Chinese patients with T2D is poor and
influenced by frailty, sex, and insulin treatment. Hence, it is crucial
to enhance the implementation of sodium-glucose cotransporter 2
inhibitors and glucagon-like peptide-1 receptor agonists in Chinese
community hospitals and strengthen the differentiation of updated
guidelines within these healthcare settings.28 Jul 2024Submitted to Clinical and Experimental Pharmacology and Physiology 21 Aug 2024Submission Checks Completed
21 Aug 2024Assigned to Editor
21 Aug 2024Review(s) Completed, Editorial Evaluation Pending
27 Aug 2024Reviewer(s) Assigned
27 Sep 2024Editorial Decision: Revise Minor